Stem cell researchers heralding ‘major scientific discovery’

January 29, 2014 - 17:55 AMT

PanARMENIAN.Net - Stem cell researchers are heralding a "major scientific discovery", with the potential to start a new age of personalized medicine, BBC News reports.

Scientists in Japan showed stem cells can now be made quickly just by dipping blood cells into acid.

Stem cells can transform into any tissue and are already being trialled for healing the eye, heart and brain.

The latest development, published in the journal Nature, could make the technology cheaper, faster and safer, according to the BBC.

The human body is built of cells with a specific role - nerve cells, liver cells, muscle cells - and that role is fixed. However, stem cells can become any other type of cell, and they have become a major field of research in medicine for their potential to regenerate the body.

Embryos are one, ethically charged, source of stem cells. Nobel prize winning research also showed that skin cells could be "genetically reprogrammed" to become stem cells (termed induced pluripotent stem cells).

Now a study shows that shocking blood cells with acid could also trigger the transformation into stem cells - this time termed STAP (stimulus-triggered acquisition of pluripotency) cells.

Dr Haruko Obokata, from the Riken Centre for Developmental Biology in Japan, said she was "really surprised" that cells could respond to their environment in this way.

She added: "It's exciting to think about the new possibilities these findings offer us, not only in regenerative medicine, but cancer as well."

Link:
Stem cell researchers heralding ‘major scientific discovery’

Failure to legislate ‘will hurt research’

Failure to legislate will hurt research

Tuesday, January 28, 2014

Even though stem cell manufacture has just been licensed in this country, the Governments ongoing failure to legislate in this area means pharmaceutical giants will still be wary of investing here, according to an expert in stem cell therapy.

CCMI General Manager Andrew Finnerty, CCMI Director Tim O'Brien, Minister Sean Sherlock and President of NUI Galway Dr. James Browne. Photograph by Aengus McMahon

Once the stem cells are harvested from the bone marrow of adult donors, they are grown in the Galway laboratory to generate sufficient quantities.

The first clinical trial using these stem cells is being funded by the Health Research Board and Science Foundation Ireland and will investigate the safety of using mesenchymal stem cells (MSCs) isolated from bone marrow for the treatment of critical limb ischemia, a complication associated with diabetes which can lead to limb amputation.

John ODea of the Irish Medical Devices Association (IMDA) said the centre was a key step.

I look forward to seeing its continued growth to assist in developing the skill sets and techniques that will be needed to embrace the new manufacturing opportunities that this exciting area will bring, he said.

The centre, one of a handful in Europe authorised for stem cell manufacture, has been developed by researchers at NUIGs regenerative medicine institute.

However, Dr Stephen Sullivan, chief scientific officer with the Irish Stem Cell Foundation warned all stem cell research operates at a pan-global level driven by big pharma and international equity firms and these players will only engage with researchers in countries where there is solid stem cell legislation in place. He welcomed the centre as a first step but said if Ireland is to compete at a top international standard, legislation remains necessary.

Originally posted here:
Failure to legislate ‘will hurt research’

Q&A – Stem cells could offer treatment for a myriad of diseases

Q&A - Stem cells could offer treatment for a myriad of diseases

Tuesday, January 28, 2014

Q.What are stem cells?

Stem cells are different however as they are at an earlier stage in cell development and this means they can make more cells and transform into different cell types such as a skin stem cell can make all the different types of skin cells.

Q. And there are two types? A.Yes. There are two types of stem cells: embryonic stem cells and adult stem cells. Embryonic stem cells can generate all cells of the human body. Adult stem calls generate a more limited number of human cell types.

Q.Why are stem cells so important? A.For many years, adult stem cells have been used to treat rare blood and certain cancers.

However, adult stem cells cant generate all cell types. For example, scientists say there doesnt appear to be an adult stem cell that can make insulin- secreting cells of the pancreas. Embryonic stem cells can, however, as they can generate all cell types and the aim of scientists is to use these embryonic cells to generate healthy tissue to replace cells compromised by disease. This means that embryonic cells are more scientifically useful.

Q. And its also embryonic cells that are the more controversial, right? A.The use of embryonic stem cells is controversial here and in other countries as certain groups believe it is morally wrong to experiment on an embryo that could become a human. Embryonic stem cells are taken from embryos left over after assisted fertility treatments. According to the Irish Stem Cell Foundation, if they werent used for research into human disease, they would be discarded as medical waste. Embryos are not created purely for research purposes they say.

Q. Why are they so useful? A. Among the conditions which scientists believe may eventually be treated by stem cell therapy are Parkinsons disease, Alzheimers disease, heart disease, stroke, arthritis, diabetes, burns and spinal cord damage. Early trials are under way for treating forms of blindness. It is also hoped we can learn from embryonic stem cells how early body tissues develops and more about the pathway of diseases. This will enable us to make better and more effective drugs.

Irish Examiner Ltd. All rights reserved

More here:
Q&A - Stem cells could offer treatment for a myriad of diseases

Making Music Videos Helps Young Cancer Patients Cope With Treatment

January 28, 2014

Ranjini Raghunath for redOrbit.com Your Universe Online

Cancer treatment through chemotherapy, radiation or stem cell therapies can be physically and mentally exhausting for patients, especially younger ones. Many factors can help them feel positive about themselves and their treatment, including spiritual practices, supportive home environments and strong social connections with friends, family and physicians.

Now, a new study shows that making music videos and writing song lyrics may also help young cancer patients better cope with their treatment.

Researchers at the Indiana University School of Nursing, Indianapolis, carried out the music therapy intervention study, which was published online in the journal Cancer.

113 young patients aged 11-24 undergoing stem cell transplants for cancer were selected randomly for the study. Half of them were given audiobooks (the control group) and the other half were given three weeks to write down song lyrics, collect images and record music videos.

Patients in the second (test) group went through six training sessions each with a music therapist, who helped them identify and write about what was important to them, and guided them in creating the videos.

It really targeted them writing, having an opportunity to write about whats important to them, co-author of the study and music therapist, Sheri Robb, told Reuters. A lot of these kids as theyre going through treatment, they tend to not talk about these things.

The patients also had a chance to share the videos they created with family and friends. After about 100 days of treatment, patients in the test group reported that making those videos helped them better connect with their loved ones.

The intervention therapy helped the young patients feel stronger, more positive and helped improve their relationships with family and physicians, based on their responses to follow-up questionnaires, the researchers reported.

Read more:
Making Music Videos Helps Young Cancer Patients Cope With Treatment

Stem-cell therapy restores faith for arthritic pets

ELLSWORTH Visitors to the Bellaire pet crisis center With a Little help From My Friends get an official welcome from Moka.

The Labrador retriever was found behind a Bellaire restaurant in 2011 and now serves as the centers mascot.

Peforming her duties has been increasingly difficult for the dog, who suffers from severe arthritis in her hips. So recently the center turned to Ellsworth veterinarian Christian Randall of North Country Veterinary Services, the first in northern Michigan to offer in-clinic adipose stem cell therapy.

The procedure uses a pets own blood and tissue to produce plasma-rich platelets and stem cells that proliferate growth in damaged areas.

Dormant stem cells are separated from adipose -- fat tissue -- and activated with an LED technology that uses three different wave lengths of light. Then the cells are injected directly into the affected area or administered intravenously to help promote regeneration. The result is a decrease in pain and lameness and increased range of motion.

Its using the bodys own repair cells to repair damage, said Trey Smith, director of laboratory services for MediVet America, which developed the technology Randall uses.

The therapy is the first treatment to help heal and slow the progression of osteoarthritis and degenerative joint disease rather than just cope with the symptoms, said Randall, who saw the results while studying at Virginia Equine Imaging and now plans to use it on equine as well as canine and feline patients.

It concentrates, speeds up and amplifies the bodys own healing power, he said.

Stem cell therapy has been around for a while, but in-clinic availability of the technology is new. Only a handful of veterinarians in Ann Arbor and Grand Rapids offer the services, said Randall, who charges $1,800 to treat a dog or cat. Repeat injections are possible with banked plasma-rich platelets and stem cells.

Before the one-day procedure, veterinarians had to send blood and tissue to an outside lab for processing, a more costly three-day procedure that requires an animal's return visit to the vet for injection.

See the article here:
Stem-cell therapy restores faith for arthritic pets

Stem cell facility opens in Co Galway

Monday 27 January 2014 14.13

The first facility in Ireland licensed to manufacture human stem cells opened in NUI Galway this morning.

The development will mean some patients suffering from certain diseases will be able to access clinical trials of stem cell therapies.

Stem cells are human cells that can develop into many types of tissue.

As a result, scientists are increasingly studying their potential for regenerating diseased or damaged tissue in people suffering the effects of certain illnesses, such as heart attacks, stroke, arthritis or diabetes.

Before they can be used widely in humans such therapies must undergo extensive clinical trials.

The first Irish licence to manufacture stem cells for this purpose was granted to the Centre for Cell Manufacturing Ireland at NUIG.

The custom-built facility will take small samples of bone marrow from adult donors and culture them in a specially designed laboratory to make billions of stem cells.

The cells will then be injected back into the donor or other patients as part of clinical trials.

The first of those trials will investigate their use in the treatment of diabetes patients who are suffering reduced blood flow to lower limbs, a symptom which often results in amputations.

Read the original post:
Stem cell facility opens in Co Galway

New method increases supply of embryonic stem cells

PUBLIC RELEASE DATE:

27-Jan-2014

Contact: Press Office pressinfo@ki.se 46-852-486-077 Karolinska Institutet

A new method allows for large-scale generation of human embryonic stem cells of high clinical quality. It also allows for production of such cells without destroying any human embryos. The discovery is a big step forward for stem cell research and for the high hopes for replacing damaged cells and thereby curing serious illnesses such as diabetes and Parkinson's disease.

Currently human embryonic stem cells are made from surplus in vitro fertilized (IVF) embryos that are not used for the generation of pregnancies. The embryos do not survive the procedure. Therefore it has been illegal in the USA to to use this method for deriving embryonic stem cell lines. Sweden's legislation has been more permissive. It has been possible to generate embryonic stem cells from excess, early IVF embryos with the permission of the persons donating their eggs and sperm.

An international research team led by Karl Tryggvason, Professor of Medical Chemistry at Karolinska Institutet in Sweden and Professor at Duke-NUS Graduate Medical School in Singapore has, together with Professor Outi Hovatta at Karolinska Institutet, developed a method that makes it possible to use a single cell from an embryo of eight cells. This embryo can then be re-frozen and, theoretically, be placed in a woman's uterus. The method is already used in Pre-implantation Genetic Diagnosis (PGD) analyses, where a genetic test is carried out on a single cell of an IVF embryo in order to detect potential hereditary diseases. If mutations are are not detected, the embryo is inserted in the woman's uterus, where it can grow into a healthy child.

"We know that an embryo can survive the removal of a single cell. This makes a great ethical difference," says Karl Tryggvason.

The single stem cell is then cultivated on a bed of a human laminin protein known as LN-521 that is normally associated with pluripotent stem cells in the embryo. This allows the stem cell to duplicate and multiply without being contaminated. Previously the cultivation of stem cells has been done on proteins from animals or on human cells, which have contaminated the stem cells through uninhibited production of thousands of proteins.

"We can cultivate the stem cells in a chemically defined, clinical quality environment. This means that one can produce stem cells on a large scale, with the precision required for pharmaceutical production," says Karl Tryggvason.

Embryonic stem cells are pluripotent and can develop into any kind of cell. This means that they can become dopamine producing cells, insulin producing cells, heart muscle cells or eye cells, to name but a few of the hopes placed on cell therapy using stem cells.

Read the original here:
New method increases supply of embryonic stem cells

Ireland’s first stem cell manufacturing centre approved at NUI Galway

Embryonic stem cells have been highly valued for their ability to turn into any type of cell in the body.

Stem cells can be manufactured for human use for the first time in Ireland, following Irish Medicines Board licensing of a new facility in Galway.

NUI Galways Centre for Cell Manufacturing Ireland aims to culture adult stem cells to tackle conditions such as arthritis, heart disease, diabetes and associated conditions.

The centre, which is one of less than half a dozen in Europe authorised for stem cell manufacture, has been developed by researchers at NUIGs regenerative medicine institute.

Stem cells serve as the bodys repair mechanism. They can be isolated from tissues such as bone marrow and fat, and cultured in laboratory settings.

More controversially, embryonic stem cells have been highly valued for their ability to turn into any type of cell in the body, but scientists can now use reprogrammed adult skin cells to create a stem cell that is very similar to embryonic versions.

The centre will be opened today by Minister of State for Research and Innovation Sen Sherlock, at a time when the Health Research Board and Science Foundation Ireland have approved funding there for clinical trials on using mesenchymal stem cells cells that can differentiate into a variety of types for treatment of critical limb ischemia, a condition associated with diabetes that can result in amputation.

The new centres director Prof Tim OBrien explained that the stem cells must be grown in the laboratory to generate sufficient quantities, following their isolation from the bone marrow of adult donors, and the facility will help Ireland to develop therapies for a broad range of clinical problems which do not have effective treatments today.

It will also allow us to translate discoveries from the basic stem cell research programme led by Prof Frank Barry at the Science Foundation Ireland-funded REMEDI to the clinic, and to be competitive for grant funding under the Horizon 2020 programme of the EU, he said.

Stem cell research in Ireland is in what scientists have described as a legislative lacuna, but this relates to use of embryonic stem cells and does not in any way inhibit the use of adult stem cells, Prof OBrien explained.

Read the original here:
Ireland’s first stem cell manufacturing centre approved at NUI Galway

Stem cells lab to open in Galway

Published Monday, 27 January 2014

A young teenager with diabetes tests his blood levels. (UTV)

Scientists behind the new facility at the National University of Ireland Galway will aim to produce adult cells to combat conditions like diabetes, arthritis and heart disease.

Stem cells created at the lab will be used in clinical trials following regulatory approval - the first of which is to test their effects on critical limb ischemia, a common complication associated with diabetes which often results in amputation.

The cells, mesenchymal stem cells (MSCs), will undergo safety tests after being isolated from bone marrow from donors and grown in the laboratory to generate sufficient quantities.

The university said it will position it as a global player in regenerative medicine.

NUI Galway's Centre for Cell Manufacturing Ireland is the first facility on the island of Ireland to receive a licence from the Irish Medicines Board to manufacture culture-expanded stem cells for human use.

It is one of less than half a dozen in Europe authorised for the process.

Some 70% of pharmaceutical companies have regenerative medicine therapies in development, with 575 active trials in cell and gene therapy under way.

There are more than 1,900 cell therapy clinical trials ongoing worldwide with regenerative medicine products generating more than $1bn in revenue in 2012.

Originally posted here:
Stem cells lab to open in Galway

Stem cell facility to open in Co Galway

Monday 27 January 2014 10.49

The first facility in Ireland licensed to manufacture human stem cells opensin NUI Galway this morning.

The development will mean some patients suffering from certain diseases will be able to access clinical trials of stem cell therapies.

Stem cells are human cells that can develop into many types of tissue.

As a result, scientists are increasingly studying their potential for regenerating diseased or damaged tissue in people suffering the effects of certain illnesses, such as heart attacks, stroke, arthritis or diabetes.

Before they can be used widely in humans such therapies must undergo extensive clinical trials.

The first Irish licence to manufacture stem cells for this purpose has been granted to the Centre for Cell Manufacturing Ireland at NUIG.

The custom-built facility will take small samples of bone marrow from adult donors and culture them in a specially designed laboratory to make billions of stem cells.

The cells will then be injected back into the donor or other patients as part of clinical trials.

The first of those trials will investigate their use in the treatment of diabetes patients who are suffering reduced blood flow to lower limbs, a symptom which often results in amputations.

See the original post here:

Stem cell facility to open in Co Galway

Stem-cell company in crisis

PROFESSOR MIODRAG STOJKOVIC/SCIENCE PHOTO LIBRARY

Advanced Cell Technology is running the only US trials of embryonic-stem-cell therapies.

Advanced Cell Technology (ACT), a biotechnology company based in Marlborough, Massachusetts, has long flirted with fame and bankruptcy.

The company is running the only US Food and Drug Administration (FDA)-approved clinical trials of embryonic stem (ES)-cell therapies. Later this month, ACT plans to report preliminary results from three trials to test the safety of its treatment for two different forms of vision loss. If all goes well, it could be the first clinical demonstration of the safety and perhaps also the therapeutic potential of ES cells.

Yet a series of financial missteps could cost ACT the opportunity to see that potential become reality. On 22 January, the firm announced that its chief executive, Gary Rabin, was stepping down. The news came a month after ACT which had US$5.5 million in cash on-hand as of 30 September 2013 announced that it would pay $4 million to settle a Securities and Exchange Commission (SEC) charge alleging that the company had illegally sold billions of shares of stock.

Thats a big hit for any biotechnology company, says Gregory Bonfiglio, a venture capitalist with Proteus Venture Partners in Portola Valley, California. This is a very painful time for them.

ACT is accustomed to the pain: it has been running on fumes for years and has repeatedly skirted bankruptcy. The company announced this week that it aims to begin the next round of its clinical trials in the second half of 2014. But its last quarterly statement, which covered the period ending 30 September, revealed that the company had only enough funds to last into the second half of 2014. ACT spokesman David Schull says that the firm is exploring all financing options and plans to expand its clinical operations to accommodate the upcoming trials.

That financing may have to carry ACT through additional legal charges. The settlement with the Securities and Exchange Commission was just one of a string of cases ACT has handled over the past few years as it dealt with the legacy left by the fundraising schemes of its previous chief executive, William Caldwell. One such case is still pending, and the SEC has launched a separate investigation of Rabin for distributing stock without reporting it to the SEC in a timely fashion.

More recently, on 2 January, the Wisconsin Alumni Research Foundation (WARF) sued ACT for breach of contract. WARF, which handles patents and licensing for the University of Wisconsin, holds a number of key ES-cell patents, and ACT struck a licensing deal with the foundation in 2007. The case has been sealed, and lawyers representing WARF did not respond immediately to requests for comment.

ACT may soon have company in the clinic. The London Project to Cure Blindness has been developing an ES cellderived therapy to treat age-related macular degeneration, a leading form of vision loss in people aged 50 and older.

Read more here:
Stem-cell company in crisis

Happy Valley Animal Hospital of Arizona Pet Vet Helps a Local Pet Start the New Year with the Resolution; Play More

Glendale, Arizona (PRWEB) January 24, 2014

Floppy, a nine year old Dachshund, struggled to get up from a laying position before his recent stem cell therapy at Happy Valley Animal Hospital. The pain from arthritis was so bad he was reluctant to move much at all, even when encouraged by his family. This holiday season Floppys owners gifted him with quality of life. Now hes bringing in the New Year with less pain and more ability to run and play again.

Floppy had been suffering from osteoarthritis in his hips and knees long enough that it was affecting other joints in his hind end. He had difficulty getting up after sitting, limped, and exhibited stiffness. Happy Valley Animal Hospitals Dr. Victor Saltzman determined Floppy was a great candidate for stem cell therapy using Vet-Stem services, and in early December scheduled Floppy for a small fat tissue collection to start the process. Floppys fat was overnighted to Vet-Stems lab in San Diego, California where it was processed into injectable doses of Floppys own stem cells. In 48 hours Dr. Saltzman received the doses back and had started Floppy on his way to recovery.

We are extremely pleased with the results. The level of pain and stiffness has decreased dramatically. Its almost like hes a puppy again! There is a night and day difference in his ability to move around and perform everyday tasks. He will occasionally get sore after a long day of activity, but its 1000% better than before his stem cell therapy, the Sobols.

Just two weeks after the stem cell injections Dr. Saltzman and the team at Happy Valley Animal Hospital received a video of Floppy running happily around the backyard, enjoying his recovered range of motion and obvious lack of pain. Although results can vary, the first peer reviewed double-blinded multicenter study for adipose-derived (fat originating) stem cell therapy use in osteoarthritis of the hip in dogs showed positive results for lameness, pain, and range of motion. Similar results have been obtained for elbows and stifles in dogs, of which stifles were a secondary area of arthritis and pain for Floppy.

Stem cells decrease pain and inflammation. Stem cells are multi-potent and can differentiate into tendon, ligament, bone, cartilage, and other tissue. The hope is that Floppys stem cells will also regenerate tissues in the joints that are causing him pain.

Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com.

About Happy Valley Animal Hospital The goal of the team at Happy Valley Animal Hospital is to provide compassionate, preventive, and top quality medical and surgical veterinary care. With the most up-to-date equipment, the team at Happy Valley Animal Hospital can provide clients and their pets in the local community with the best healthcare and service possible. By offering and maintaining these goals, the team at Happy Valley Animal Hospital hopes to enhance the lives of their clients by allowing their pets to live long, happy lives. As a team, Happy Valley Animal Hospital always considers the client perspective and tries to put themselves in their shoes or paws.

Read this article:
Happy Valley Animal Hospital of Arizona Pet Vet Helps a Local Pet Start the New Year with the Resolution; Play More

stem cell therapy treatment for cerebral palsy sri lanka by dr alok sharma, mumbai, india – Video


stem cell therapy treatment for cerebral palsy sri lanka by dr alok sharma, mumbai, india
improvement seen in just 3 months after stem cell therapy treatment for cerebral palsy by dr alok sharma, mumbai, india. Stem Cell Therapy done date 4/10/201...

By: Neurogen Brain and Spine Institute

Visit link:
stem cell therapy treatment for cerebral palsy sri lanka by dr alok sharma, mumbai, india - Video

Insulin-producing beta cells from stem cells

Jan. 23, 2014 The Wnt/-catenin signaling pathway and microRNA 335 are instrumental in helping form differentiated progenitor cells from stem cells. These are organized in germ layers and are thus the origin of different tissue types, including the pancreas and its insulin-producing beta cells. With these findings, Helmholtz Zentrum Mnchen scientists have discovered key molecular functions of stem cell differentiation which could be used for beta cell replacement therapy in diabetes. The results of the two studies were published in the journal Development.

The findings of the scientists of the Institute of Diabetes and Regeneration Research (IDR) at Helmholtz Zentrum Mnchen (HMGU) provide new insights into the molecular regulation of stem cell differentiation. These results reveal important target structures for regenerative therapy approaches to chronic diseases such as diabetes.

During embryonic development, organ-specific cell types are formed from pluripotent stem cells, which can differentiate into all cell types of the human body. The pluripotent cells of the embryo organize themselves at an early stage in germ layers: the endoderm, mesoderm and ectoderm. From these three cell populations different functional tissue cells arise, such as skin cells, muscle cells, and specific organ cells.

Various signaling pathways are important for this germ layer organization, including the Wnt/-catenin signaling pathway. The cells of the pancreas, such as the beta cells, originate from the endoderm, the germ layer from which the gastrointestinal tract, the liver and the lungs also arise. Professor Heiko Lickert, director of the IDR, in collaboration with Professor Gunnar Schotta of LMU Mnchen, showed that the Wnt/-catenin signaling pathway regulates Sox17, which in turn regulates molecular programs that assign pluripotent cells to the endoderm, thus inducing an initial differentiation of the stem cells. In another project Professor Lickert and his colleague Professor Fabian Theis, director of the Institute of Computational Biology (ICB) at Helmholtz Zentrum Mnchen, discovered an additional mechanism that influences the progenitor cells. miRNA-335, a messenger nucleic acid, regulates the endodermal transcription factors Sox17 and Foxa2 and is essential for the differentiation of cells within this germ layer and their demarcation from the adjacent mesoderm. The concentrations of the transcription factors determine here whether these cells develop into lung, liver or pancreas cells. To achieve these results, the scientists combined their expertise in experimental research with mathematical modeling.

"Our findings represent two key processes of stem cell differentiation," said Lickert. "With an improved understanding of cell formation we can succeed in generating functional specialized cells from stem cells. These could be used for a variety of therapeutic approaches. In diabetes, we may be able to replace the defective beta cells, but regenerative medicine also offers new therapeutic options for other organ defects and diseases."

Diabetes is characterized by a dysfunction of the insulin-producing beta cells of the pancreas. Regenerative treatment approaches aim to renew or replace these cells. An EU-funded research project ('HumEn'), in which Lickert and his team are participating, shall provide further insights in the field of beta-cell replacement therapy.

The aim of research at Helmholtz Zentrum Mnchen, a partner in the German Center for Diabetes Research (DZD), is to develop new approaches for the diagnosis, treatment and prevention of major common diseases such as diabetes mellitus.

See the article here:
Insulin-producing beta cells from stem cells

stem cell therapy treatment for Right Hemiparesis Cerebral Palsy by dr alok sharma, mumbai, india – Video


stem cell therapy treatment for Right Hemiparesis Cerebral Palsy by dr alok sharma, mumbai, india
improvement seen in just 5 days after stem cell therapy treatment for Right Hemiparesis Cerebral Palsy by dr alok sharma, mumbai, india. Stem Cell Therapy do...

By: Neurogen Brain and Spine Institute

See the original post:

stem cell therapy treatment for Right Hemiparesis Cerebral Palsy by dr alok sharma, mumbai, india - Video

stem cell therapy treatment for global developmental delay by dr alok sharma, mumbai, india – Video


stem cell therapy treatment for global developmental delay by dr alok sharma, mumbai, india
improvement seen in just 5 days after stem cell therapy treatment for ______ by dr alok sharma, mumbai, india. Stem Cell Therapy done date 17/12/2013 After S...

By: Neurogen Brain and Spine Institute

Excerpt from:

stem cell therapy treatment for global developmental delay by dr alok sharma, mumbai, india - Video